Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in biomarkers research, from development and diagnostics to precision medicine

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Biomarkers for Clinical Development

Surrogate Biomarkers in NASH and Liver Cirrhosis: Qualifying for Clinical Trial Validation and Legislative Success

Highly involved treatment scenarios and prognostics are required to properly assess best-practice approaches for investigating issues posed by NASH and liver cirrhosis. Surrogate biomarkers present a less invasive approach to assessing these outcomes.
Read More
Biomarkers for Clinical Development

Keytruda sees Trial Success in Treating Endometrial Cancer Patients

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.
Read More
Biomarkers for Clinical Development

Eli Lilly Focus on Phase III Trial for Alzheimer’s Treatment Following FDA Fast Lane Setback

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.
Read More
Biomarkers for Clinical Development

FDA Approves Merck-Developed KEYTRUDA for Non-Small Cell Lung Cancer Therapy

KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival in patients following surgical resection and platinum-based chemotherapy.
Read More
Biomarkers for Clinical Development

FDA Commits to Increasing Diversity in Clinical Trials

The move follows steps announced by the EMA and the MHRA to ensure clinical trials are more reflective of patient populations.
Read More
Biomarkers for Clinical Development

Predicting Parkinson’s Disease with Machine Learning

Understanding machine learning’s role in providing a biomarker for the neurological condition.
Read More
Biomarkers for Clinical Development

Toxicity Markers of Cognitive Deterioration in Young Cancer Sufferers

Cancer-related cognitive impairment in young adults found pre-treatment, study reports.
Read More
Biomarkers for Clinical Development

Implementing Patient-Centricity into Biomarker Clinical Trials

How can we better define patient-centric clinical trials within the drug development process?
Read More
Biomarkers for Clinical Development

Cervical Indicators of HIV Risk Found

Study finds predictive link between genital herpes and HIV.
Read More
Biomarkers for Clinical Development

Novel Microbial Immunotherapies for Bladder Cancer Treatment

The potential oncolytic applications of Salmonella ZH9 include its use in mitigating diseases such as bladder cancer, with a demonstrated therapeutic effect in cancer models.
Read More
Biomarkers for Clinical Development

Patient Engagement in Biomarker Development

Christopher Conn, Director of Diagnostics Strategy at Amgen, leads a Discussion Group on patient testing and engagement in biomarker clinical trials.
Read More
Biomarkers for Clinical Development

Biomarkers for NASH Symposium: Most Anticipated Presentation

Discover key event highlights from Oxford Global's upcoming Biomarkers for NASH Symposium 2022.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biomarkers